Today we are happy to announce that we have taken a step towards improving the quality of life of the patients suffering from respiratory health issues. This idea comes to life with the alveofit platform. If we look at the public health figures, respiratory illness is the number one killer and each passing day numbers are increasing. And within respiratory illnesses, Asthma and COPD are the biggest contributors.
With an estimated 1.5-2 crore asthma patients, at least one in every 10 asthma patients globally lives in India. Globally, the economic costs associated with asthma exceed those of TB and HIV/AIDS combined. Considered the most common chronic disease among children, Asthma is prevalent in all countries, whether they are developed or underdeveloped. In fact, over 80 percent of asthma deaths, according to the World Health Organization (WHO), occur in low and lower-middle-income countries (1).
alveoFit as an ecosystem designed and developed specifically to manage asthma and COPD more effectively. This is a mobile-enabled tool integrated with state of the art indigenously developed hospital-grade spirometer “alveoair” to measure lung performance and MDI inhaler sensor to track the inhaler medication adherence.
Learn more about alveofit.
Allow patient to drive – out of the box
Even after a lot of advancement in healthcare to improve the quality of care, still, the management of Asthma and COPD are the biggest and frustrating challenge. We have made significant steps to develop new medications and build an understanding of complexity but patients are still suffering due to lack of constant monitoring and its effective management.
alveoFit is the platform that allows patients to sit at the driver seat and manage their illness more effectively as soon as they are out of the physician’s office. And allow physicians to know their patients’ current health status remotely which indirectly contributes to improved care delivery. Patients will be more informed about their lung health status by using alveoair, more aware of flare-ups rather keep remembering what is the cause behind it. With the help of alveodot, timely controller medication administration leads to greater medication adherence and provides more control over their asthma.
Patients will be more aware of surrounding air quality which may cause sudden exacerbation. In the management of asthma or COPD, most importantly patients should be educated about their current asthma control status and timely and right intervention will significantly reduce exacerbation and patients can live symptom-free lives as we move along in longer run.
Plug predictive analysis and AI engine to improve individuals control over their asthma or COPD
Thought of knowing my upcoming asthma attack and what could be the cause behind it, is like I am on cloud nine and I know when this will be going happen so I can be in a position to avoid such instances. Really?? Is this possible?? Or just a sci-fi plot of some play?.
Yes, this is possible now and alveoFit is working towards it. Soon alveoFit platform will have this capability to let patients know about their future attacks and cause behind this by harnessing data captured over the period of time. It will not only help patients but measure data points in clinical practice.
Let’s take a small example here to understand what happens when patients visit the physician office. Generally, patients with Asthma conditions visit physician offices every three months and that patient-practitioner visit lasts only for 15 mins. Just before the appointment patient has experienced 2190 hours of asthma condition in treating himself (or not treating) but during the visit, a physician is spending 15 mins of experience to understand the complexity of illness either by reviewing patient’s physical diary (highly unlikely because the majority doesn’t follow this practice) or Q & A and history documentation and giving next course of treatment. Is this sufficient to understand the individual asthma condition? Or let the alveoFit system document the 2190 hours of experience and review that experience during the visit. Now this sound more effective way of examining the patient provides the next course of action.
Because, We know that environmental factors, medication adherence, a patient’s home location, emotional and economic stress, and many other social determinants of health are critical causes for uncontrolled asthma and all this information in medical records at physician offices are not adequately captured. (2)
Additionally if translated into clinical practice, can potentially link genetic traits to phenotypes that can, for example, predict response, or nonresponse, to medications such as albuterol and steroids or identify an individual’s risk for cortisol suppression
By analyzing past events and all the above mentioned factors, giving precise information on future events and making patients more aware can bring down uncontrolled asthma and help patients to live a quality life. (3) (3) https://pubmed.ncbi.nlm.nih.gov/30649013/
Reduction in out of pocket expenses in the management of asthma-COPD
Asthma is a long-term disease and patients really need to keep the inflammation under control by taking the right preventer medication at the right time and not just relying on short term symptom relief from a blue inhaler.
We know that preventer inhalers can be incredibly effective at controlling symptoms and preventing people from being hospitalized or even from dying of asthma, yet our study has found that out-of-pocket costs are preventing many from accessing medicines which can be life-saving.
The study, published in The Journal of Allergy and Clinical Immunology: In Practice, found that young male adults were most likely to under-use asthma treatments.
This was compounded by doctors being largely unaware that out-of-pocket costs were a significant concern for many of their patients, or that some preventers had lower out-of-pocket costs for patients than others.
The mean annual direct cost for asthma treatment was ₹18,737/year. The mean annual cost due to medications, doctor’s visit, investigations, and hospitalization was ₹7,427, ₹2089/year, ₹1103/year, and ₹62,500/year, respectively. An asthma patient lost an average of 17 working days/year. The mean annual indirect cost for an asthma patient was ₹25,358, whereas, for the caregivers was ₹19,971. (4)
In a nutshell, this lung condition will cause a lot of loss, and if the right intervention at the right time with effective management can bring down the cost by a huge margin. Our sole objective is making patients with asthma COPD conditions more aware and should have strong control over conditions and live symptom-free life with the alveoFit ecosystem.